BIO (Bio-Rad Laboratories) Cyclically Adjusted Revenue per Share: $101.23 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIO Bio-Rad Laboratories Inc BIO
71 GF Score
Price $334.24
GF Value $317.78
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories Cyclically Adjusted Revenue per Share?

Bio-Rad Laboratories BIO +2.69% 71 Cyclically Adjusted Revenue per Share is $101.23 as of Mar. 2026. GuruFocus rates BIO with a GF Score™ of 71/100 and a GF Value™ of $317.78 (Fairly Valued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bio-Rad Laboratories's adjusted revenue per share for the three months ended in Mar. 2026 was $21.964. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $101.23 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Bio-Rad Laboratories's average Cyclically Adjusted Revenue Growth Rate was 3.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 2.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Bio-Rad Laboratories was 11.60% per year. The lowest was 2.10% per year. And the median was 7.20% per year.

As of today (2026-08-03), Bio-Rad Laboratories's current stock price is $334.24. Bio-Rad Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $101.23. Bio-Rad Laboratories's Cyclically Adjusted PS Ratio of today is 3.30.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bio-Rad Laboratories was 9.77. The lowest was 2.10. And the median was 3.74.


Bio-Rad Laboratories  (NYSE:BIO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bio-Rad Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=334.24/101.23
=3.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bio-Rad Laboratories was 9.77. The lowest was 2.10. And the median was 3.74.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bio-Rad Laboratories Cyclically Adjusted Revenue per Share Related Terms


Bio-Rad Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bio-Rad Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Rad Laboratories Cyclically Adjusted Revenue per Share Chart

Bio-Rad Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 86.45 92.19 94.72 96.64 99.36

Bio-Rad Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 97.83 98.74 99.67 99.36 101.23

BIO vs GKOS, BRKR, GMED: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Rad Laboratories Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Cyclically Adjusted PS Ratio falls into.


BIO
71GF Score
Bio-Rad Laboratories Inc BIO
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Rad Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bio-Rad Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=21.964/330.2130*330.2130
=21.964

Current CPI (Mar. 2026) = 330.2130.

Bio-Rad Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 17.465 241.018 23.928
201609 17.146 241.428 23.451
201612 19.171 241.432 26.221
201703 16.718 243.801 22.643
201706 16.819 244.955 22.673
201709 17.774 246.819 23.779
201712 20.604 246.524 27.599
201803 18.280 249.554 24.188
201806 19.058 251.989 24.974
201809 17.996 252.439 23.540
201812 20.419 251.233 26.838
201903 18.402 254.202 23.905
201906 18.990 256.143 24.481
201909 18.794 256.759 24.171
201912 20.616 256.974 26.492
202003 18.931 258.115 24.219
202006 17.861 257.797 22.878
202009 21.484 260.280 27.256
202012 26.129 260.474 33.125
202103 24.077 264.877 30.016
202106 23.747 271.696 28.862
202109 24.717 274.310 29.754
202112 24.214 278.802 28.679
202203 23.388 287.504 26.862
202206 23.196 296.311 25.850
202209 22.897 296.808 25.474
202212 24.601 296.797 27.371
202303 22.753 301.836 24.892
202306 23.203 305.109 25.112
202309 21.631 307.789 23.207
202312 23.659 306.746 25.469
202403 21.404 312.332 22.629
202406 22.486 314.175 23.634
202409 23.216 315.301 24.314
202412 23.841 315.605 24.944
202503 20.941 319.799 21.623
202506 23.931 322.561 24.499
202509 24.254 324.800 24.658
202512 25.658 324.054 26.146
202603 21.964 330.213 21.964

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $101.23 mean?
Bio-Rad Laboratories (BIO) has a Cyclically Adjusted Revenue per Share of $101.23 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bio-Rad Laboratories and its competitors.
Is Bio-Rad Laboratories' Cyclically Adjusted Revenue per Share too high?
Bio-Rad Laboratories' current Cyclically Adjusted Revenue per Share is $101.23. Overall, Bio-Rad Laboratories has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Cyclically Adjusted Revenue per Share compare to GKOS and BRKR?
Bio-Rad Laboratories' Cyclically Adjusted Revenue per Share of $101.23 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bio-Rad Laboratories and its competitors. Bio-Rad Laboratories's current Cyclically Adjusted Revenue per Share is $101.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (BIO) is currently considered Fairly Valued. The stock's GF Value™ is $317.78, compared to a current price of $334.24 — trading 5.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $101.23. Bio-Rad Laboratories' overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bio-Rad Laboratories (BIO), the current Cyclically Adjusted Revenue per Share is $101.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Rad Laboratories (BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be overvalued. The current stock price of $334.24 is trading 5.2% above its estimated GF Value™ of $317.78. GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.

Key valuation signals for BIO:

  • Cyclically Adjusted Revenue per Share: $101.23
  • GF Value™: $317.78 vs. price of $334.24 (5.2% above fair value)
  • GF Score™: 71/100 with 8 warning signs

No single metric tells the full story. See the BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bio-Rad Laboratories Business Description

Other Exchanges BIO.B:USABUWA:Germany
Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
71GF Score

Get the complete analysis for BIO

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$334.24
Price
$317.78
GF Value